Skip to main content

News

| Article
Austrian Article by Franziska Dzugan in "Profil" about adverse drug effects

Sehr viel mehr Menschen sterben an unerwünschten Wirkungen von Medikamenten als im Straßenverkehr. Mit der Zahl der Arzneien, die jemand einnimmt, steigt das Risiko dramatisch. Was aber, wenn selbst die Ärzte nicht weiterwissen?

Read more about Austrian Article by Franziska Dzugan in "Profil" about adverse drug effects >
| Article
Article on "Personalized Medicine" in Plattform Life Science

Seit jeher versuchen Mediziner, ihren Patienten die bestmögliche Behandlung zukommen zu lassen. Doch ist der Mensch ein kompliziertes Wesen, will sagen, jeder Mensch reagiert anders auf die ihm verschriebene Dosis an Medikamenten oder Therapien. Ganz ähnlich verhält es sich mit den Krankheiten. Ursache, Verlauf oder Härtegrad hängen von einer Vielzahl von Faktoren ab. Dies bezieht sich nicht nur auf die genetische Ausstattung der Betroffenen, ihr Alter oder ihr Geschlecht. Auch externe Umwelteinflüsse und individuelle Lebensstile haben einen Einfluss. Die Folgen dieser Umstände sind maßgeblich, denn viele konventionell hergestellte Wirkstoffe erzielen längst nicht (mehr) die erhoffte Wirkung oder bringen nicht beabsichtigte Nebenwirkungen.

Read more about Article on "Personalized Medicine" in Plattform Life Science >
| Press release
German hospital Robert-Bosch-Krankenhaus Stuttgart and bio.logis GIM integrate pharmacogenetics into clinical practice—a milestone for personalized medicine

Personalized medicine is on everybody’s lips. For many patients it is a ray of hope because it promises better therapy and treatment results for the individual patient. Taking into account a patient’s genetic make-up is of particular importance here. Stuttgart’s Dr. Margarete Fischer-Bosch institute for clinical pharmacology (IKP) at the Robert-Bosch-Krankenhaus (RBK) is one of the leading pharmacogenetics institutions worldwide and works on how hereditary factors influence drug efficacy. Together with bio.logis GIM, a company based in Frankfurt, RBK will implement a newly developed IT platform (Genetic Information Management Suite, GIMS) and integrate it with its hospital information system using existing interfaces. GIMS enables RBK to automate the translation of its patients’ pharmacogenetic results into clinically exploitable therapy recommendations. For the first time, patients access their personal pharmacogenetic findings via a Web portal and use them for future medical treatment.

Read more about German hospital Robert-Bosch-Krankenhaus Stuttgart and bio.logis GIM integrate pharmacogenetics into clinical practice—a milestone for personalized medicine >
| Press release
Personalized medicine: Medical University of Vienna (MUW) to collaborate with bio.logis GIM in pharmacogenetics

Within the framework of U-PGx, an EU project for promoting the use of pharmacogenetic insights in healthcare, the Medical University of Vienna (MUW) will implement the Genetic Information Management Suite (GIMS) developed by bio.logis Genetic Information Management GmbH. The platform is the first of its kind to largely automatically translate genetic analysis results from laboratories into easily understood diagnostic reports, including the right treatment recommendations from the internationally renowned KNMP (the Royal Dutch Pharmacists Association). Here, the MUW uses the Diagnostic Report Module (GIMS.DRM) in combination with a QR-based safety code card, developed by MUW, for patients. This card is used to make patients’ personal analysis results accessible.

Read more about Personalized medicine: Medical University of Vienna (MUW) to collaborate with bio.logis GIM in pharmacogenetics >
| Article
bio.logis GIM on GenomeWeb

An article about bio.logis GIM's distribution agreement with PGS.Holland for GenomeWeb:

Bio.logis, PGS.Holland Ink Distribution Pact for Genetic Diagnosis Software
NEW YORK (GenomeWeb) – Bio.logis Genetic Information Management and PGS.Holland have entered into an agreement to market Bio.logis' Genetic Information Management Suite (GIMS) in Belgium, the Netherlands, and Luxembourg (Benelux), Scandinavia, and the UK.

Read more about bio.logis GIM on GenomeWeb >
| Press release
bio.logis GIM GmbH concludes a distribution agreement with PGS.Holland BV

bio.logis Genetic Information Management (GIM) and PGS.Holland, have entered into a distribution collaboration to market the Genetic Information Management Suite (GIMS) in Benelux countries, Scandinavia, and the UK.

Read more about bio.logis GIM GmbH concludes a distribution agreement with PGS.Holland BV >
| Article
bio.logis GIM on GenomeWeb

An article about bio.logis GIM by Justin Petrone for GenomeWeb:

Bio.logis Readies New Clinical Genetic Data Interpretation Tools Amid Growing Customer Interest
NEW YORK (GenomeWeb) – Bio.logis, a Frankfurt, Germany-based informatics company, is planning multiple upgrades to its flagship clinical genetic data interpretation tool as it continues to win new customers across Europe. CMO Maike Post said that the firm will launch two new analysis modules for its Genetic Information Management Suite next year, in addition to a new pharmacogenomics mobile application.

Read more about bio.logis GIM on GenomeWeb >
| Press release
Laboratory group Laboratoires Réunis capitalizes Genetic Information Management software suite for complex laboratory reports

Laboratoires Réunis group is a further client for bio.logis Genetic Information Management GmbH’s “Genetic Information Management Suite (GIMS)”, specially developed for genetic diagnostics. Usage will initially focus on establishing the creation of highly complex diagnostic reports with a maximum degree of efficiency and automation.

Read more about Laboratory group Laboratoires Réunis capitalizes Genetic Information Management software suite for complex laboratory reports >
| Article
bio.logis GIM launches first version of an iOS mobile app for personalized drug therapy

The “pharma.sensor” developed by bio.logis Genetic Information Management GmbH (bio.logis GIM) is a new mobile app for pharmacogenomics. The app shows whether certain DNA variants have to be considered for the safe efficacy of a drug. With this knowledge, the app user can identify if genotyping is useful prior of starting a drug therapy. The drug check is performed by simply entering a drug name or scanning the barcode on the packaging. The app is available in German and English via the Apple app store and is free of charge.

Read more about bio.logis GIM launches first version of an iOS mobile app for personalized drug therapy >
| Article
ESHG 2017: Post-Event News

bio.logis Genetic Information Management GmbH was present at the European Human Genetics Conference from May 27 to 30, 2017.

Read more about ESHG 2017: Post-Event News >